



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 9/48, 9/66</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/59482</b> <b>(43) International Publication Date:</b> 12 October 2000 (12.10.00)
<b>(21) International Application Number:</b> PCT/US00/08426 <b>(22) International Filing Date:</b> 29 March 2000 (29.03.00) <b>(30) Priority Data:</b> 9907715.8 1 April 1999 (01.04.99) GB <b>(71) Applicant (for all designated States except US):</b> R.P. SCHERER CORPORATION [US/US]; Suite 200, 645 Martinsville Road, Basking Ridge, NJ 07920 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> PERRY, Elizabeth, A. [GB/GB]; 1 Copper Beeches, Cricklade Road, Highworth, Swindon SN6 7BJ (GB). CHANDLER, Susan [GB/GB]; 43 Herd Street, Wiltshire, Marlborough (GB). FERDINANDO, Josephine, Joan, Christine [GB/GB]; 16 Lytham Close, Monkton Park, Chippenham, Wiltshire SN15 2XM (GB). DE NIJS, Henrik [NL/NL]; Hermelijnedreef 27, NL-5343 XC Oss (NL). <b>(74) Agent:</b> NICKEY, Donald, O.; Cardinal Health, Inc., 7000 Cardinal Place, Dublin, OH 43017 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING LONG-CHAIN TRIGLYCERIDES AND LIPOPHILIC SURFACTANTS <b>(57) Abstract</b> <p>The invention disclosed herein relates to liquid pharmaceutical compositions for oral administration which contain a drug or active ingredient dissolved in a liquid vehicle or carrier in which the liquid vehicle comprises a glyceride of a long chain fatty acid having from 14 to 22 carbon atoms and a lipophilic surfactant having an HLB of less than 10. Compositions of the invention provide increased drug or active ingredient stability and contain a liquid vehicle which is less reactive with the drug or active ingredient than free fatty acids. In one embodiment, the liquid pharmaceutical compositions contain testosterone undecanoate, a long chain triglyceride, and lauroglycol. The compositions can be orally administered and formulated in soft gel or hard shell capsule form.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING LONG-CHAIN TRIGLYCERIDES AND LIPOPHILIC SURFACTANTS

### **Field of the Invention**

The invention relates to pharmaceutical compositions for oral administration. In particular, the invention relates to liquid pharmaceutical compositions suitable for softgel encapsulation.

### 5 **Background of the Invention**

A number of drugs are known to require formulation in the presence of fatty acids, such as oleic acid, to provide optimum conditions for bioavailability. For example, long-chain fatty acids can be predisposed for lymphatic absorption, and therefore, are useful in pharmaceutical formulations in which the lymphatic system is  
10 the desired target site for the active ingredient. One of the problems associated with the formulations containing fatty acids is that chemical instability can arise due to their acidic nature and the presence of reactive carboxyl groups. Esterification can occur with drug molecules containing alcohol groups or transesterification of ester molecules.

15 In the past, this problem has been solved by continuing to use free fatty acids in formulations which are encapsulated in softgel capsules and storing the capsules under refrigerated conditions to reduce the rate of reaction between the drug and fatty acids. However, where the drug is not sufficiently soluble in the formulation, cold storage methods result in crystallization which in turn necessitates equilibrating the

capsules at room temperature to ensure crystal dissolution prior to consumption.

Accordingly, complex storage regimens are required throughout the supply chain for the use of such formulations.

Lacy et al. in Patent Cooperation Treaty WO 95/24893 published September 21, 1995 discloses a carrier system for a hydrophobic drug which comprises a digestible oil and a pharmaceutically acceptable surfactant for dispersing the oil *in vivo* upon administration of the carrier system, the surfactant comprising a hydrophilic surfactant component which does not substantially inhibit the lipolysis of the digestible oil, and a lipophilic surfactant component which substantially reduces the inhibitory effect of the hydrophilic surfactant. Suitable digestible oils are complete or partial esters of medium chain (C<sub>8</sub>-C<sub>12</sub>) or long-chain (C<sub>14</sub> – C<sub>22</sub>) fatty acids with low molecular weight (up to C<sub>6</sub>) mono-, di- or polyhydric alcohols. Medium chain length triglycerides or long chain tri- and diglyceride mixtures which may contain monoglycerides are particularly preferred. Fractionated coconut oil is a preferred oil.

The lipophilic surfactants used include fatty acids; mono- and/or diglycerides of fatty acids; acetic, succinic, lactic, citric and/or tartaric esters of mono and/or diglycerides of fatty acids; propylene glycol mono- and/or di-esters of fatty acids; polyglycerol esters of fatty acids; castor oil ethoxylates; acid and ester ethoxylates; and sorbitan esters of fatty acids.

The hydrophilic surfactants used have a hydrophilic/lipophilic balance (HLB) value greater than 10 and include phospholipid; polyoxyethylene sorbitan fatty acid derivatives; castor oil or hydrogenated castor oil ethoxylates; fatty acid ethoxylates;

alcohol ethoxylates; polyoxyethylene, polyoxypropylene co-polymers and block co-polymers; anionic surfactants and alkylphenol surfactants.

The formulations may contain ethanol as a co-solvent and formulations containing up to 15% by weight ethanol are disclosed.

5           Perry et al. in Patent Cooperation Treat WO 97/40823 published November 6, 1997 discloses a pharmaceutical composition comprising a hydrophobic drug; a digestible oil selected from triglycerides or propylene glycol esters of medium chain length ( $C_8$ - $C_{12}$ ) and/or long chain length ( $C_{13}$ - $C_{22}$ ) fatty acids; propylene glycol monolaurate (lauroglycol), a lipophilic surfactant which comprises a glyceride of a  $C_5$  to  $C_{10}$  fatty acid; and a hydrophilic surfactant which is a polyoxyethylene  
10           hydrogenated castor oil, wherein the digestible oil is present in an amount in the range from 3.0 to 12.0% by weight of the composition and the weight ratio of hydrophilic surfactant to lipophilic surfactant is in the range of 1:1.5 to 1:2.5. The formulations may contain ethanol as a co-solvent for the drug and formulations containing 15-25%  
15           by weight ethanol are disclosed.

There still exists the need for pharmaceutical compositions having improved stability which promote systemic absorption.

### **Summary of the Invention**

20           The invention discloses a liquid pharmaceutical composition wherein the active ingredient is dissolved in a liquid vehicle comprising a combination of long chain glycerides and lipophilic surfactant. The composition according to the

invention are stable and promote systemic absorption and can be used for oral formulations containing drugs or active ingredients susceptible to the adverse affects of carboxyl groups in carrier ingredients. The invention is particularly useful for oral formulations containing testosterone undecanoate (also referred to as TU).

5           According to the invention there is provided a liquid pharmaceutical composition comprising a drug dissolved in a liquid vehicle, the liquid vehicle comprising:

- a) a glyceride of a long chain fatty acid having a chain containing from 14 to 22 carbon atoms and is present in an amount from about 15% to about 10 70% by weight, preferably from about 15% to about 60% by weight of said liquid vehicle;
- b) a lipophilic surfactant having an HLB of less than 10 and present in an amount of from about 30% to about 60% by weight of said liquid vehicle.

The composition according to the invention contains a liquid vehicle which is 15 substantially devoid of free fatty acids and contains less than 10% by weight ethanol.

The composition can further comprise a hydrophilic surfactant, which can be present in an amount of from about 0% to about 35% by weight of the liquid vehicle.

In one embodiment of the invention, there is provided a liquid pharmaceutical composition for oral administration having testosterone undecanoate dissolved in a 20 liquid vehicle, the liquid vehicle consisting essentially of:

- a) a glyceride of a long chain fatty acid having a chain containing from 14 to 22 carbon atoms; and

b) lauroglycol.

It has now been found that the stability problem associated with free fatty acids can be avoided by the use of glycerides in which the fatty acids are esterified with glycerol to form a neutral compound which is less reactive. Thus, the invention  
5 minimizes or excludes the use of free fatty acids in the compositions.

Suitable glycerides for use in the invention are mono-, di- and triglycerides. Preferred glycerides are triglycerides, as they contain the highest fatty acid content. Long chain glycerides can liberate long chain fatty acids following lipolysis in the gastrointestinal tract. The long chain triglycerides are desirable to promote lymphatic  
10 absorption in a manner similar to the respective fatty acids. See, for example, Henk de Nijs, Acta Technol., 33(4) pp.163-168 (1987), which discusses the enhancement of lymphatic absorption by using triglycerides and different absorption mechanisms involved with long and medium chain fatty acids.

In the present invention, the presence of the lipophilic surfactant, and  
15 optionally the additional hydrophilic surfactant, enhances the solubility of drugs in the liquid triglyceride carrier while maintaining the stability of the composition.

The invention is particularly useful in pharmaceutical compositions containing drugs, i.e., active ingredients, compounds, pro-drugs and the like, which encounter stability problems when combined with free fatty acids. Preferred compositions of the  
20 invention are those containing testosterone undecanoate (TU).

**Detailed Description of the Invention**

As used herein and in the claims, the terms “drug” and “active ingredient” are used synonymously to refer to pharmaceutical compounds or molecular structures.

When used within the context of the invention, the terms refer to pharmaceutical  
5 compounds which can be used in association with the liquid carrier of the invention to produce the resulting pharmaceutical composition.

The phrase “substantially free from free fatty acid” as used within the context of describing the pharmaceutical compositions according to the invention is intended to mean that the liquid carrier contains less than 1% by weight of fatty acids that are  
10 not esterified to a polyol such as glycol.

The invention includes a liquid pharmaceutical composition comprising a drug dissolved in a liquid vehicle, the liquid vehicle comprising:

- a) a glyceride of a long chain fatty acid having a chain containing from 14 to 22 carbon atoms and is present in an amount from about 15% to about  
15 70% by weight, preferably from about 15% to about 60% by weight of said vehicle; and
- b) a lipophilic surfactant having an HLB of less than 10 and present in an amount of from about 30% to about 60% by weight of said vehicle.

The composition according to the invention contains a liquid vehicle which is  
20 substantially free from free fatty acids and preferably contains less than 10% by weight ethanol.



The composition can further comprise a hydrophilic surfactant, which can be present in an amount of from about 0% to about 35% by weight of the vehicle.

Suitable drugs or active ingredients which can be used in the invention are those which encounter stability problems in the presence of free fatty acids. Such  
5 drugs or pro-drugs include, but are not limited to, compounds containing ester groups which can result in transesterification, compounds containing amide groups, compounds containing alcohol groups which can result in ester formation, and compounds which contain amine groups which can result in amide formation. Examples of such drugs or active ingredients include testosterone undecanoate,  
10 hydroxyprogesterone hexanoate and other steroid esters, retinyl palmitate, fenofibrate, halofantrine, retinol and tocopherol. Preferred compositions of the invention are those containing testosterone undecanoate as the active ingredient.

Suitable long chain ( $C_{14}$ - $C_{22}$ ) triglycerides for use in the invention include, but are not limited to, arachis oil, soya bean oil, castor oil, corn oil, safflower oil, olive  
15 oil, apricot kernel oil, sesame oil, cotton seed oil, sunflower seed oil, palm oil and rapeseed oil. The triglycerides are present in amounts of from about 15% to about 70% by weight of the liquid vehicle, preferably in the amount of from about 40% to about 60% by weight of the liquid vehicle.

Suitable long chain mono-glycerides which can be used include glyceryl  
20 mono-oleate.

Suitable lipophilic surfactants for use in the invention are those having an HLB value of less than 10 ( $HLB < 10$ ). Lipophilic surfactants having an HLB of less

than 10 which can be used include, but are not limited to: mono- and di-glycerides of fatty acids; acetic, succinic, lactic, citric and tartaric esters of mono- and di-glycerides of fatty acids; propylene glycol mono- and di-esters of fatty acids; polyglycerol esters of fatty acids; castor oil and hydrogenated castor oil ethoxylates; acid and ester  
5 ethoxylates; sorbitan esters of fatty acids; unsaturated polyglycolized glycerides, alcohol ethoxylates; and polyoxyethylene-polyoxypropylene co-polymers and block co-polymers.

Examples of mono- and di-glycerides of fatty acids which can be used as the lipophilic surfactant include, for example, glyceryl mono/di-caprylate, glyceryl mono-  
10 di-caprylate/caprate, glyceryl mono-caprylate, glyceryl mono-stearate, glyceryl mono-/di-ricinoleate, glyceryl caprylate/caprate, glyceryl mono-oleate, glyceryl dilaurate and glyceryl monostearate

Acetic, succinic, lactic, citric and/or tartaric esters of mono- and/or di-glycerides of fatty acids which can be used as the lipophilic surfactant include  
15 distilled acetylated monoglycerides, caprylic/capric diglyceryl succinate, mono/di-succinylated monoglycerides, glyceryl stearate citrate, glyceryl monostearate/citrate/-lactate, glyceryl cocate/citrate/lactate.

Propylene glycol mono- and/or di-esters of fatty acids which can be used include, for example, lauroglycol (propylene glycol monolaurate) and propylene  
20 glycol dicaprylate/dicaprate

Polyglycerol esters of fatty acids suitable as the lipophilic surfactant include polyglyceryl oleate.

Castor oil or hydrogenated castor oil ethoxylates having low ethoxylate content and HLB less than 10 can also be used, for example, 5 moles of ethylene oxide reacted with 1 mole of castor oil.

Acid and ester ethoxylates formed by reacting ethylene oxide with fatty acids or glycerol esters of fatty acids which can be used include, polyoxyethylene (4) lauric acid, polyoxyethylene (2) stearic acid, polyoxyethylene (3) stearic acid, glyceryl 12 EO dioleate.

Sorbitan esters of fatty acids suitable for use as the lipophilic surfactant include, for example, sorbitan monolaurate, sorbitan monooleate, sorbitan trioleate, sorbitan tristearate.

Examples of unsaturated polyglycolized glycerides include polyoxyethylated apricot kernel oil, polyoxyethylated corn oil, polyoxyethylated hydrogenated oil.

Alcohol ethoxylates which can be used include polyoxyethylated (3) oleyl ether, polyoxyethylated (2) oleyl ether.

Examples of polyoxyethylene-polyoxypropylene co-polymers and block co-polymers can also be used as the lipophilic surfactant.

The lipophilic surfactant is used in an amount ranging from about 30% to about 60% by weight, typically from about 40% to about 60% by weight of the liquid vehicle.

Preferred lipophilic surfactants for use in the liquid vehicle are propylene glycol mono- and/or di-esters of fatty acids. Most preferred is lauroglycol (propylene glycol monolaurate) as the lipophilic surfactant.

In a further embodiment, a pharmaceutically acceptable hydrophilic surfactant having an HLB value greater than 10 ( $HLB > 10$ ) can be used in addition to the long chain glyceride and lipophilic surfactant ingredient of the present invention.

Examples of hydrophilic surfactants which can be used include:

- 5           a) Phospholipids, in particular lecithins, preferably soyabean lecithins.
- b) Polyoxyethylene sorbitan fatty acid derivatives, for example,  
polyoxyethylene (20) monolaurate, polyoxyethylene (20) monopalmitate,  
polyoxyethylene (20) monopalmitate, polyoxyethylene (20) sorbitan monostearate,  
and polyoxyethylene (20) monooleate
- 10          c) Castor oil or hydrogenated castor oil ethoxylates, for example,  
polyoxyethylene (35) castor oil, polyoxyethylene (40) hydrogenated castor oil,  
polyoxyethylene (40) castor oil and polyoxyethylene (60) hydrogenated castor oil.
- d) Fatty acid ethoxylates, for example, polyoxyethylene (8) stearate,  
polyoxyethylene (30) monolaurate, polyoxyethylene (20) stearate, polyoxyethylene  
15       (15) oleate.
- e) Alcohol ethoxylates, for example, polyoxyethylene (10) oleyl ether,  
polyoxyethylene (30) oleyl ether, polyoxyethylene (20) C12-C14 fatty ether.
- f) Polyoxyethylene-polyoxypropylene co-polymers and block co-polymers.
- g) Alkylphenol surfactants, for example, polyoxyethylene (9-10)  
20       nonylphenol, polyoxyethylene (9) nonylphenol.
- h) Saturated polyglycolized medium chain triglycerides, for example, a  
combination of glyceryl caprylate and polyethylene glycol (8) caprylate/caprate.

The compositions can contain up to 40% by weight of hydrophilic surfactant based on the weight of the liquid vehicle.

Other conventional ingredients or additives can be used in the compositions in accordance with the invention. For example, anti-oxidants such as d-alpha-  
5 tocopherol, BHA, BHT and co-solvents such as ethanol, diethylene glycol monoethylether, plasticizers such as propylene glycol, and the like.

Compositions according to the invention can be prepared using conventional methods such as those described in Lacy et al., Patent Cooperation Treaty WO95/24893 published September 21, 1995. A typical process for preparing  
10 carrier systems of the invention begins with weighing out the oil component into a suitable stainless steel vessel and then weighing the lipophilic surfactant and adding it to the container. Mixing of the two liquids is effected by the use of a homogenizing mixer or other high shear device. If the material is solid at room temperature, sufficient heat is applied to ensure fluidity without chemical decomposition. If used,  
15 the hydrophilic surfactant is added to the other two components. If a hydrophilic solvent is used it is added last with mixing. The drug is then weighed and added to the combined liquids and mixing continued until either a homogenous solution or suspension is prepared. The formulation is then de-aerated before encapsulation in either soft or hard capsules. In some instances, the fill formulation may be held at  
20 elevated temperature using a suitable jacketed vessel to aid processing.

The compositions can be encapsulated in softgel or hard shell capsules. Methods of softgel encapsulation are taught in Theory and Practice of Industrial

Pharmacy (Lachman & Leiberman, 2<sup>nd</sup> Edition, publ. Henry Kimpton Publishers, London). Methods of liquid-fill hardshell encapsulation are disclosed in Hardcapsules – Development and Technology, edited by K. Ridgeway, (published by Pharmaceutical Press) (1987).

- 5           The invention will now be illustrated by the following Examples, which are not intended to be construed as limitations to the invention:

**EXAMPLES:**  
Examples 1A through 14A

10                           Preparation of Liquid Vehicle Formulations

Fourteen liquid vehicle formulations were prepared as measured in parts by weight and contained the following respective ingredients:

<u>Example:</u>	<u>Ingredients:</u>	<u>% (w/w):</u>
1	Soya Bean oil	15
	Lauroglycol	60
	Polyoxyethylene (20) monopalmitate	25
2	Arachis oil	25
	Lauroglycol	40
	Polyoxyethylene (20) monopalmitate	35
3	Arachis oil	40
	Lauroglycol	60
4	Arachis oil	40
	Glyceryl mono-oleate	60
5	Castor oil	60
	Lauroglycol	40

6	Soya Bean oil	50
	Lauroglycol	50
7	Soya Bean oil	20
	Glyceryl mono/di-caprylate	50
	Glyceryl caprylate and polyethylene glycol (8) caprylate/caprate	30
8	Castor oil	60
	Glyceryl mono/di-caprylate	40
9	Castor oil	40
	Lauroglycol	55
	Ethanol	5
10	Castor oil	30
	Glyceryl mono/di-caprylate	40
	Polyoxyethylene (35) castor oil	30
11	Castor oil	50
	Lauroglycol	30
	Glyceryl caprylate and polyethylene glycol (8) caprylate/caprate	20
12	Arachis oil	40
	Glyceryl mono-oleate	30
	Polyoxyethylene (35) castor oil	25
	Ethanol	5
13	Arachis oil	25
	Lauroglycol	60
	Glyceryl caprylate and polyethylene glycol (8) caprylate/caprate	15
14	Arachis oil	60
	Glyceryl mono/di-caprylate	40

## Examples 1B through 14B

Preparation of Pharmaceutical Compositions containing Liquid Vehicle Formulations

5           Compositions containing an active ingredient and liquid vehicle were prepared by mixing 88 parts by weight of each liquid vehicle formulation as prepared in Examples 1A through 14A together with 12 parts by weight of testosterone undecanoate (TU). The resulting composition contained testosterone undecanoate in stable form which was suitable for encapsulation in the preparation of softgel  
10   capsules.

**EXAMPLE 15**Comparative Stability Test of Testosterone Undecanoate (TU)

Accelerated stability trials were conducted using pharmaceutical compositions  
15   containing testosterone undecanoate as the active ingredient in samples using the liquid vehicle according to the invention and a liquid vehicle control sample.

Five samples containing testosterone undecanoate were prepared in accordance with the formulations depicted in Examples 1B through 5B. The control sample containing testosterone undecanoate in combination with oleic acid was  
20   prepared. All six samples were then stored for a period of three months.

Following the three month period, each of the resulting samples was analyzed for testosterone undecanoate content. The five samples containing composition prepared according to the invention were found to contain at least 86% and even at



least 90% of the active ingredient, whereas the control sample was found to contain less than 70% of the original testosterone undecanoate content.

In conclusion, the data demonstrates that the samples prepared according to the invention exhibited an increased longevity of the original active ingredient (i.e., testosterone undecanoate) in storage when compared to the control sample containing the active ingredient with oleic acid.

### **Industrial Applicability**

The invention is useful in the production of pharmaceutical compositions for oral administration wherein the drug or active ingredient is known to have stability problems associated with the use of free fatty acids. Examples of such drugs or active ingredients include sex hormones such as testosterone undecanoate. The compositions of the invention enhance the solubility of such compounds and improve the storage stability thereof, and can be advantageously used in soft gel and hard shell capsular formulations.

The complete disclosures of all patents, patent applications, and publications are incorporated herein by reference as if each were individually incorporated by reference. The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.

## CLAIMS

We claim:

1. A liquid pharmaceutical composition having a drug dissolved in a liquid vehicle, said liquid vehicle comprising:
  - a) a glyceride of a long chain fatty acid;
  - b) a lipophilic surfactant having an HLB of less than 10; andwherein said liquid vehicle is substantially free from free fatty acid.
2. A liquid pharmaceutical composition according to claim 1, wherein the drug is testosterone undecanoate.
3. The liquid pharmaceutical composition according to claim 1, wherein the glyceride of a long chain fatty acid is present in an amount from about 15% to about 70% by weight in the liquid vehicle, and wherein the lipophilic surfactant is present in an amount from about 30% to about 60% by weight in the liquid vehicle.
4. The liquid pharmaceutical composition according to claim 1, wherein the glyceride is a long chain triglyceride having 14 to 22 carbon atoms.
5. The liquid pharmaceutical composition according to claim 4, wherein the long chain triglyceride is selected from the group consisting of arachis oil, soya bean oil, castor oil, corn oil, safflower oil, olive oil, apricot kernel oil and sesame oil, and combinations thereof.
6. The liquid pharmaceutical composition according to claim 1, wherein the glyceride of a long chain fatty acid is a mono- or diglyceride.

7. The liquid pharmaceutical composition according to claim 6, wherein the glyceride of a long chain fatty acid is the monoglyceride glyceryl mono-oleate.
8. The liquid pharmaceutical composition according to claim 1, wherein the lipophilic surfactant is selected from the group consisting of: mono- and diglycerides of fatty acids; acetic, succinic, lactic and tartaric esters of mono- and di-glycerides of fatty acids; propylene glycol mono- and di-esters of fatty acids; castor oil and hydrogenated castor oil ethoxylates; acid and ester ethoxylates; sorbitan esters of fatty acids; unsaturated polyglycolized glycerides; alcohol ethoxylates; and polyoxyethylene-propylene co-polymers and block co-polymers, and combinations thereof.
9. The liquid pharmaceutical composition according to claim 8, wherein the lipophilic surfactant is a propylene glycol mono-ester of a fatty acid.
10. The liquid pharmaceutical composition according to claim 9, wherein the lipophilic surfactant is lauroglycol.
11. The liquid pharmaceutical composition according to claim 1, further comprising a hydrophilic surfactant.
12. The liquid pharmaceutical composition according to claim 11, wherein the hydrophilic surfactant is selected from the group consisting of phospholipids, polyoxyethylene sorbitan fatty acid derivatives, castor oil or hydrogenated castor oil ethoxylates, fatty acid ethoxylates, alcohol ethoxylates, polyoxyethylene-polyoxypropylene copolymers and block co-polymers,

alkylphenol surfactants and polyglycolized medium chain triglycerides, and combinations thereof.

13. The liquid pharmaceutical composition according to claim 1, further comprising ethanol.
14. The liquid pharmaceutical composition according to claim 13 which contains less than 15% by weight ethanol.
15. A liquid pharmaceutical composition for oral administration having testosterone undecanoate dissolved in a liquid vehicle, said liquid vehicle consisting essentially of:
  - a) a glyceride of a long chain fatty acid having from 14 to 22 carbon atoms;  
and
  - b) lauroglycol.
16. The liquid pharmaceutical composition according to claim 15, wherein the glyceride of a long chain fatty acid is a triglyceride.
17. A soft gel capsule containing the liquid pharmaceutical composition according to claim 1.
18. A soft gel capsule containing the liquid pharmaceutical composition according to claim 15.
19. A hard shell capsule containing the liquid pharmaceutical composition according to claim 1.
20. A hard shell capsule containing the liquid pharmaceutical composition according to claim 15.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/08426

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) :A61K 9/48, 9/66

US CL :424/451, 452, 455, 456

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/451, 452, 455, 456

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,645,856 A (LACY et al) 08 July 1997, see columns 3-9, column 12, lines 32-36, examples 1-7, claims 1-16.	1-20



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* & * document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

19 JUNE 2000

Date of mailing of the international search report

31 JUL 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JAMES M. SPEAR

Telephone No. (703) 308-1235